FDA Fast-Tracks Liquidia Drug for Painful Systemic Sclerosis Complication
Liquidia stock rises after the FDA grants Fast Track status to YUTREPIA for treating Raynaud’s phenomenon in systemic sclerosis.
The FDA said it will speed up review of a Liquidia medicine that helps people with a painful hand condition. This is a positive signal that doctors and regulators think the medicine could really help patients, which is why people got excited about the company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.